Epitalon Online: Cost, Prescription Requirements, and What the Research Actually Shows

Print or save as PDF

What Is Epitalon?

Epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide: alanine, glutamic acid, aspartic acid and glycine, or Ala-Glu-Asp-Gly [1]. Its molecular weight is about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland, and FDA says it first appears to have been synthesized in 1999 [1].

FDA treats epitalon and epithalamin as different substances, so studies of epithalamin are not studies of epitalon [1].

Is Epitalon Approved Anywhere?

No. FDA's July 2026 review found no USP or National Formulary monograph for epitalon and no listing in the European or Japanese pharmacopeias [1]. It found no approved epitalon product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, and none authorized by the European Medicines Agency [1].

Epitalon did hold an FDA orphan drug designation for retinitis pigmentosa, granted September 2, 2010 and withdrawn on January 6, 2016 [1]. A 2015 analysis identified epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [1][7].

Does a Prescription Make It Available?

Under federal compounding rules, a state-licensed pharmacy or physician may compound only with bulk substances that comply with a USP or National Formulary monograph, are components of FDA-approved drug products, or appear on FDA's list of bulk drug substances that can be used in compounding [2]. Epitalon meets none of those three conditions [1][2]. It also appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and in none of the categories on FDA's list for outsourcing facilities [8][9][2]. FDA's category 1 policy, under which the agency generally does not act against compounders that meet its conditions, does not cover epitalon [8][2].

What exists instead is a draft. HHS filed an enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192, scheduled for publication October 30, 2026) naming epitalon among six peptides, alongside BPC-157, KPV, MOTS-c, Semax and TB-500 [3][6]. It covers epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [3][6]. The same notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public' [3].

FDA's review found no pharmacy that compounds epitalon and no outsourcing facility reporting it, although a Kentucky pharmacy was reported by the US Attorney's office to have compounded and distributed epitalon products from October 25, 2018 to April 1, 2020 [1]. Compounded drugs in general are not FDA-approved: FDA does not verify their safety, effectiveness or quality before they are marketed [10].

What Is Sold Online

Epitalon is sold online as research-use-only vials (10 mg to 50 mg), capsules and oral sprays, and promoted as an anti-aging peptide that lengthens telomeres [1]. These are not approved products.

What the Research Actually Shows

FDA found only three human studies of epitalon: two using a sublingual spray in night-shift workers and one using an injection beside the eye in retinitis pigmentosa [1]. FDA evaluated only insomnia and found no study of epitalon in people with insomnia and no sleep outcomes measured; the other nominated uses, such as anti-aging and telomere lengthening, were not evaluated for lack of information [1].

The sublingual melatonin study

A placebo-controlled study enrolled 75 healthy women aged 40 to 50, mostly night-shift workers; 40 of them had low melatonin output and were split into two groups of 20 [1]. They received a sublingual spray delivering about 0.5 mg per day, or placebo, for 20 days [1]. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo, and 83% versus 25% of participants were described as improved in mood and physical condition, but no sleep outcomes were measured, blinding was not specified, and the study was short and small [1].

The retinitis pigmentosa study

An older controlled clinical study in patients with degenerative retinal lesions reported a positive clinical effect in 90% of the cases, without giving sample sizes or design details in the abstract; FDA describes the study as involving an injection beside the eye [1][11]. It has not been replicated and is not a modern randomized trial [1][11].

The telomerase cell-culture work

Adding epitalon to telomerase-negative human fetal fibroblast cultures induced the catalytic subunit of telomerase, telomerase activity and telomere elongation [12]. That is a cell-culture result, not an outcome measured in people [12]. FDA also warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic; the mouse studies of cancer and chromosome damage were too limited, with one fixed dose, female mice only and short exposure, to establish safety [1].

The 2026 review

A narrative review in the International Journal of Molecular Sciences searched PubMed and Google Scholar through September 22, 2026 and concluded that human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, and that no adequately powered randomized trial has established efficacy [4]. Its summary verdict is 'biologically active but clinically unproven' [4].

What Dose Do People Use?

There is no approved dose [1]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles, with one site suggesting a course every four months; FDA treated those figures as marketing, not evidence [1]. The human studies FDA found used a sublingual spray delivering about 0.5 mg per day for 20 days, and a parabulbar (beside the eye) injection for retinitis pigmentosa [1].

What to Watch For

There is no approved epitalon product and therefore no FDA label with an adverse-reaction profile [1]. FDA found no clinical study that assessed epitalon's safety; one small study reported no safety data, and a Russian-language abstract said only 'no side effects' without a dose, route or number of people [1]. FDA also raised an immunogenicity concern with subcutaneous injection, since injectable peptides may pose a risk from aggregation and impurities [1][13]. FDA's adverse-event database search through December 8, 2025, and its food and supplement complaint system search through December 5, 2025, retrieved no epitalon reports [1].

FDA's page on bulk substances that may raise significant safety risks lists epitalon in its table of substances that were previously in category 2 and were withdrawn by the nominators; FDA said removal from category 2 was not a finding that epitalon is safe, and its stated concern was that it 'has not identified safety-related information regarding epitalon for the proposed route of administration' [13]. FDA found no pharmacokinetic data for epitalon [1].